Data characterizing a panel of biodegradable cross-linked polyester implants for sustained delivery of an anti-viral drugMendeley Data
Tenofovir alafenamide (TAF) is currently administered orally to patients for treatment of chronic hepatitis B virus infection and as a part of a combination therapy for human immunodeficiency virus (HIV) infection. A long-acting delivery system could provide several advantages as a formulation strat...
Saved in:
Main Authors: | Sungmin Jung, Jack Bufton, Zeqing Bao, Wonjoon Cho, Dean Aguiar, Christine Allen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Data in Brief |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340924011442 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01) -
Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection
by: Kazuto Tajiri, et al.
Published: (2024-12-01) -
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01) -
Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
by: Yu-Xuan Song, et al.
Published: (2025-01-01) -
Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study
by: Amir M. Mohareb, et al.
Published: (2024-12-01)